Future Considerations

Pain is a complex sensory experience, contributed to by cognitive factors, environment (setting, society, and culture), experience, and gender, and significantly modulated by the central nervous system. We have focused here on the most tractable aspect of the experience of pain, namely the nociceptor, because most, but not all, pain is associated with activation of a nociceptor in peripheral tissue. The drug receptors/ion channels briefly discussed above are all present on nociceptors and thus are targets for drug development. These same receptors are present in the central nervous system as well, and effects on central P2, ASLC, or TRP receptors may also contribute to desirable analgesic or antihyperalgesic effects, or to unanticipated and unwanted effects.


1. Calixto, J. B.; Kassuya, C. A. L.; Andre, E.; Ferreira, J. Pharmacol. Ther. 2005, 106, 179-208.

2. Ferrer-Montiel, A.; Garcia-Martinez, C.; Morenilla-Palao, C.; Garcia-Sanz, N.; Fernandez-Carvajal, A.; Fernandez-Ballester, G.; Planells-Cases, R. Eur. J. Biochem. 2004, 271, 1820-1826.

3. Szallasi, A.; Appendino, G. J. Med. Chem. 2004, 47, 2717-2723.

4. Holzer, P. Eur. J. Pharmacol. 2004, 500, 231-241.

5. van der Stelt, M.; Di Marzo, V Eur. J. Biochem. 2004, 271, 1827-1834.

6. Cortright, D. N.; Szallasi, A. Eur. J. Biochem. 2004, 271, 1814-1819.

7. Birder, L. A.; Nakamura, Y; Kiss, S.; Nealen, M. L.; Barrick, S.; Kanai, A. J.; Wang, E.; Ruiz, G.; De Groat, W C.; Apodaca, G. et al. Nat. Neurosci. 2002, 5, 856-860.

8. Honore, P.; Wismer, C. T.; Mikusa, J.; Zhu, C. Z.; Zhong, C.; Gauvin, D. M.; Gomtsyan, A.; El Kouhen, R.; Lee, C. H.; Marsh, K. et al. J. Pharmacol. Exp. Ther. 2005, 314, 410-421.

9. Davis, J. B.; Gray, J.; Gunthorpe, M. J.; Hatcher, J. P; Davey, P. T.; Overend, P; Harries, M. H.; Latcham, J.; Clapham, C.; Atkinson, K. et al. Nature 2000, 405, 183-187.

10. Jones, R. C. W, ILL.; Xu, L.; Gebhart, G. F J. Neurosci. 2005, 25, 10981-10989.

11. Waldmann, R.; Champigny, G.; Lingueglia, E.; De Weille, J. R.; Heurteaux, C.; Lazdunski, M. Ann. N. Y. Acad. Sci. 1999, 868, 67-76.

12. Krishtal, O. Trends Neurosci. 2003, 26, 477-483.

13. Voilley, N.; de Weille, J.; Mamet, J.; Lazdunski, M. J. Neurosci. 2001, 21, 8026-8033.

14. Voilley, N. Curr. Drug Targets Inflamm. Allergy 2004, 3, 71-79.

15. Llles, P; Ribeiro, J. A. Curr. Top. Med. Chem. 2004, 4, 831-838.

16. Liu, X. J.; Salter, M. W Curr. Opin. Investig. Drugs 2005, 6, 65-75.

17. Jarvis, M. F; Burgard, E. C.; McGaraughty, S.; Honore, P.; Lynch, K.; Brennan, T J.; Subieta, A.; Van Biesen, T; Cartmell, J.; Bianchi, B. et al. Proc. Natl. Acad. Sci. USA 2002, 99, 17179-17184.

18. McGaraughty, S.; Wismer, C. T; Zhu, C. Z.; Mikusa, J.; Honore, P.; Chu, K. L.; Lee, C. H.; Faltynek, C. R.; Jarvis, M. F Br. J. Pharmacol. 2003, 140, 1381-1388.

19. Cockayne, D. A.; Dunn, P M.; Zhong, Y; Rong, W; Hamilton, S. G.; Knight, G. E.; Ruan, H. Z.; Ma, B.; Yip, P; Nunn, P. et al. J. Physiol. 2005, 567, 621-639.

20. Vlaskovska, M.; Kasakov, L.; Rong, W; Bodin, P.; Bardini, M.; Cockayne, D. A.; Ford, A. P; Burnstock, G. J. Neurosci. 2001, 21, 5670-5677.

21. Varney, M. A.; Gereau, R. W Curr. Drug Targets CNS Neurol. Disord. 2002, 1, 283-296.

22. Eide, K.; Stubhaug, A.; Oye, I.; Breivik, H. Pain 1995, 61, 221-228.

23. Jevtovic-Todorovic, V; Todorovic, S. M.; Mennerick, S.; Powell, S.; Dikranian, K.; Benshoff, N.; Zorumski, C. F; Olney, J. W Nat. Med. 1998, 4, 460-463.

24. LoGrasso, P.; McKelvy, J. Curr. Opin. Chem. Biol. 2003, 7, 452-456.

25. Ogata, N.; Ohishi, Y Jpn. J. Pharmacol. 2002, 88, 365-377.

26. Lai, J.; Porreca, F; Hunter, J. C.; Gold, M. S. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 371-397.

27. Lai, J.; Gold, M. S.; Kim, C. S.; Bian, D.; Ossipov, M. H.; Hunter, J. C.; Porreca, F Pain 2002, 95, 143-152.

28. Porreca, F; Lai, J.; Bian, D.; Wegert, S.; Ossipov, M. H.; Eglen, R. M.; Kassotakis, L.; Novakovic, S.; Rabert, D. K.; Sangameswaran, L. et al. Proc. Natl. Acad. Sci. USA 1999, 96, 7640-7644.

29. Laird, J. M.; Souslova, V; Wood, J. N.; Cervero, F J. Neurosci. 2002, 22, 8352-8356.

30. Erichsen, H. K.; Hao, J. X.; Xu, X. J.; Blackburn-Munro, G. Eur. J. Pharmacol. 2003, 458, 275-282.

31. McGivern, J. G.; McDonough, S. I. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 457-478.

32. Doering, C. J.; Zamponi, G. W Curr. Pharm. Des. 2005, 11, 1887-1898.

33 . Ertel, E . A. ; Campbell, K. P. ; Harpold, M . M . ; Hofmann, F ; Mori, Y ; Perez-Reyes, E . ; Schwartz, A. ; Snutch, T P ; Tanabe, T. ; Birnbaumer, L. et al. Neuron 2000, 25, 533-535.

34. Catterall, W A.; Striessnig, J.; Snutch, T P; Perez-Reyes, E. Pharmacol Rev. 2003, 55, 579-581.

35. Altier, C.; Zamponi, G. W Trends Pharmacol. Sci. 2004, 25, 465-470.

36. Smith, M. T; Cabot, P J.; Ross, F B.; Robertson, A. D.; Lewis, R. J. Pain 2002, 96, 119-127.

37. Hatakeyama, S.; Wakamori, M.; Ino, M.; Miyamoto, N.; Takahashi, E.; Yoshinaga, T; Sawada, K.; Imoto, K.; Tanaka, I.; Yoshizawa, T et al. Neuroreport 2001, 12, 2423-2427.

38. Saegusa, H.; Kurihara, T; Zong, S.; Kazuno, A.; Matsuda, Y; Nonaka, T.; Han, W; Toriyama, H.; Tanabe, T EMBO J. 2001, 20, 2349-2356.

39. McIntosh, M.; Cruz, L. J.; Hunkapiller, M. W; Gray, W R.; Olivera, B. M. Arch. Biochem. Biophys. 1982, 218, 329-334.

40. Jones, R. M.; Bulaj, G. Curr. Pharm. Des. 2000, 6, 1249-1285.

41. Wermeling, D. P. Pharmacotherapy 2005, 25, 1084-1094.


Thomas E Prisinzano was born in New York City, and studied at the University of Delaware, where he obtained a BS in 1995, and Virginia Commonwealth University, where he completed his PhD in 2000 under the direction of Professor RA Glennon. He was then awarded an Intramural Research Training Award Fellowship to study in the laboratory of Dr Kenner C Rice at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). While at NIDDK, he worked on drugs of abuse and treatment agents. Subsequently, he took up his present position as an Assistant Professor in Division of Medicinal and Natural Products Chemistry at the University of Iowa in May 2003. His scientific interests include the development of novel analgesics, in particular, the development of novel compounds to study the neurochemical mechanisms of drug dependence and tolerance.

G F (Jerry) Gebhart was born in Chicago, and earned a BS (1967, Pharmacy) at the University of Illinois (Chicago) and MS and PhD degrees (in 1969 and 1971, respectively, Pharmacology) at the University of Iowa. After 2 years of postdoctoral training with Herbert H Jasper in Montreal, he returned to Iowa where he rose to the rank of Professor in 1981 and was Head of the Department of Pharmacology from 1996 to 2006. He is currently Director of the Pittsburgh Center for Pain Research at the University of Pittsburgh. He spent a sabbatical year with Manfred Zimmermann in Heidelberg, Germany, in the early 1980s. His scientific interests include descending modulation of pain and mechanisms of nociception, particularly visceral nociception and visceral hypersensitivity, which have been supported by NIH funding continuously since the early 1970s.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 321-326

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment